TRANSFORMATIVE MEDICINES
FOR CHRONIC AUTOIMMUNE
AND INFLAMMATORY DISEASES
Late breaking news presentation slides
EADV 2024
Mission
Legacy Healthcare is developing transformative medicines for the treatment of autoimmune and inflammatory diseases, with an immune-sparing mode of action, allowing safe chronic use.
Our first drug, Coacillium, achieves this goal.
Coacillium cutaneous solution has been filed for approval with EMA for the treatment of alopecia areata, a debilitating autoimmune dermatological disease with intense psychological impact on all patients, especially
in children.
Members of the Board
Saad Harti
Chairman
Geert Cauwenbergh
PhD
Director
Johanne Barthelet
Director
Peter Nicholson
Board member
Management Team
News & events
Sep 2024
Clinical data presentation
GHM
Barcelona, SP
May 2024
Clinical data presentation
AEDV
Madrid, SP
May 2024
Clinical data presentation
ESPD
Kosice, SK
Apr 2024
AAD 2024 conference
review
American Medical Journal
Mar 2024
AAD 2024
Peer-reviewed
conference report
Medicom Medical
Publishers
Dec 2023
Clinical data presentation
"JDP
Paris, FR
"
Oct 2023
Late-breaking news
presentation slides
EADV 2023
Germany
Sept 2023
Broadcasted interview
"Legacy Healthcare
Botanical Drugs"
Jul 2023
Broadcasted interview
"Botanicals in pharma:
Potential and pitfalls"
Jan 2023
Press Release
"Positive Top-Line Results
from Phase 2/3 Trial"